Namenda, Axura, Ebixa (memantine) is a small molecule pharmaceutical. Memantine was first approved as Namenda on 2002-05-15. It is used to treat alzheimer disease in the USA. It has been approved in Europe to treat alzheimer disease. It is known to target glutamate receptor ionotropic, NMDA 2C. Namenda's patent is valid until 2029-03-24 (FDA).
|Trade Name||Axura, Ebixa|
|Drug Class||Antivirals/antiparkinsonians (adamantane derivatives)|